Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Esophageal01: ifinatamab deruxtecan versus investigator's choice chemotherapy in pretreated advanced or metastatic ESCC
2023-509630-19-00Phase 3Authorised
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, open-label trial of ifinatamab deruxtecan in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Overall survival. Planned start Jul 2025; status: authorised.
02
Drugs
ifinatamab deruxtecan
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on 2023-509630-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509630-19-00.